Overview of Glp-1 Receptor Dimerization
The glucagon-like peptide-1 receptor ( GLP -1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP -1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are ...
The glucagon-like peptide-1 receptor ( GLP -1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP -1Rs eliciting glucose-dependent insulin secretion.
Key Details About Glp-1 Receptor Dimerization
The glucagon-like peptide-1 receptor ( GLP -1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP -1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are peptide based, and there is substantial interest in small molecule modulators for the GLP -1R ...
As we can see from the illustration, Glp 1 Receptor Dimerization has many fascinating aspects to explore.
Currently, approved therapeu- ticsacting at this receptor are peptide based, and there issubstantial interest insmall molecule modulators forthe GLP -1R. Using a variety energy transfer techniques, we demonstrate that the of resonance GLP -1R forms homodimers and that transmembrane helix 4 (TM4) providesthe primary dimerization interface.
(PDF) Glucagon
The glucagon-like peptide-1 receptor ( GLP -1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP -1Rs ...
Share this article Abstract The glucagon-like peptide-1 receptor ( GLP -1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP -1Rs eliciting glucose-dependent insulin secretion.
As we can see from the illustration, Glp 1 Receptor Dimerization has many fascinating aspects to explore.
Dimerizationoligomerization of the extracellular domain of the GLP1 ...
Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 ( GLP-1 ) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another compound, CHU-128. Compounds from these patent series, including PF 06882961, are currently in clinical trials for treatment of type 2 diabetes.
Structural pharmacology and mechanisms of GLP
Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 ( GLP-1 ) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another compound, CHU-128. Compounds from these patent series, including PF 06882961, are currently in clinical trials for treatment of type 2 diabetes.
